Emergent Biosolutions (EBS) Stock
Specialty biopharmaceutical company producing vaccines and public health products. Here's the price, business snapshot, and what's worth knowing about Emergent Biosolutions in September 2026.
Emergent BioSolutions Inc (EBS) is a specialty biopharmaceutical company focused on public‑health countermeasures, including vaccines, therapeutics and related devices. The business mixes commercial products with government and public‑health contracts, and also offers contract manufacturing capacity — a model that can generate steady, often large-scale orders but can make revenue lumpy. With a market capitalisation of about $504.17M, EBS sits in the small‑cap space where operational setbacks or contract timing can have an outsized impact on the share price. Key investor considerations include the company’s exposure to government procurement cycles, regulatory scrutiny of manufacturing quality, and any product concentration or litigation. While a capable manufacturing footprint and specialist product portfolio can be attractive, execution risk and policy dependence are material. This summary is for educational purposes only and is not personal financial advice; suitability depends on your circumstances and you should seek independent advice if unsure.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Emergent BioSolutions' stock with a target price of $11, indicating growth potential.
Financial Health
Emergent Biosolutions is performing well with strong revenue and profits, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Government Contracts
A significant portion of revenue comes from government and public‑health contracts, which can provide scale but be lumpy and sensitive to policy decisions.
Products for Public Health
The company focuses on vaccines, therapeutics and devices for emergencies and infectious diseases — an area with enduring demand, though regulatory hurdles matter.
Manufacturing Risk & Reward
In‑house manufacturing can be a competitive advantage but brings operational and quality risks; past execution issues show how production affects value.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
